Toll Free: 1-888-928-9744

Angina (Angina Pectoris) - Pipeline Review, H2 2015

Published: Nov, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Angina (Angina Pectoris) - Pipeline Review, H2 2015


Global Markets Directs, Angina (Angina Pectoris) - Pipeline Review, H2 2015, provides an overview of the Angina (Angina Pectoris)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Angina (Angina Pectoris) Overview 8
Therapeutics Development 9
Pipeline Products for Angina (Angina Pectoris) - Overview 9
Angina (Angina Pectoris) - Therapeutics under Development by Companies 10
Angina (Angina Pectoris) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Angina (Angina Pectoris) - Products under Development by Companies 14
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 15
Baxalta Incorporated 15
Bayer AG 16
Cardiolynx AG 17
Gilead Sciences, Inc. 18
Juventas Therapeutics, Inc. 19
Kuhnil Pharmaceutical Co., Ltd. 20
Lacer, S.A. 21
Lee's Pharmaceutical Holdings Limited 22
LegoChem Biosciences, Inc 23
Milestone Pharmaceuticals, Inc. 24
Taxus Cardium Pharmaceuticals Group Inc. 25
ViroMed Co., Ltd. 26
Angina (Angina Pectoris) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
aladorian sodium - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alferminogene tadenovec - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BAY-606583 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CLC-1201 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CLC-1280 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
eleclazine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
JVS-100 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
KI-1007 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LA-419 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LA-8045 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MSP-2017 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Activate Soluble Guanylate Cyclase for Angina Pectoris - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VM-202 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ZK-001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Angina (Angina Pectoris) - Recent Pipeline Updates 59
Angina (Angina Pectoris) - Dormant Projects 68
Angina (Angina Pectoris) - Discontinued Products 70
Angina (Angina Pectoris) - Product Development Milestones 71
Featured News & Press Releases 71
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 71
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 73
May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 74
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 75
Nov 19, 2012: Cardium Therapeutics Announces Patent Award for Rights to Cardiovascular Gene Therapy For Treatment Of Heart Disease 76
Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280 78
Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 79
Apr 18, 2011: Lees Pharma Completes Phase I Study Of Anti-Platelet Drug Declotana 80
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 80
Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 80

Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83
List of Tables

Number of Products under Development for Angina (Angina Pectoris), H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Angina (Angina Pectoris) - Pipeline by Baxalta Incorporated, H2 2015 15
Angina (Angina Pectoris) - Pipeline by Bayer AG, H2 2015 16
Angina (Angina Pectoris) - Pipeline by Cardiolynx AG, H2 2015 17
Angina (Angina Pectoris) - Pipeline by Gilead Sciences, Inc., H2 2015 18
Angina (Angina Pectoris) - Pipeline by Juventas Therapeutics, Inc., H2 2015 19
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2015 20
Angina (Angina Pectoris) - Pipeline by Lacer, S.A., H2 2015 21
Angina (Angina Pectoris) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 22
Angina (Angina Pectoris) - Pipeline by LegoChem Biosciences, Inc, H2 2015 23
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals, Inc., H2 2015 24
Angina (Angina Pectoris) - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2015 25
Angina (Angina Pectoris) - Pipeline by ViroMed Co., Ltd., H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Number of Products by Stage and Target, H2 2015 29
Number of Products by Stage and Mechanism of Action, H2 2015 31
Number of Products by Stage and Route of Administration, H2 2015 33
Number of Products by Stage and Molecule Type, H2 2015 35
Angina (Angina Pectoris) Therapeutics - Recent Pipeline Updates, H2 2015 59
Angina (Angina Pectoris) - Dormant Projects, H2 2015 68
Angina (Angina Pectoris) - Dormant Projects (Contd..1), H2 2015 69
Angina (Angina Pectoris) - Discontinued Products, H2 2015 70 

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.